Senior Project Advisor

Jeff Grimm

Document Type

Project

Publication Date

Spring 2023

Keywords

Cannabidiol (CBD), substance use disorders (SUDs), intraperitoneal (IP) injection

Abstract

Cannabidiol (CBD) is a cannabinoid derived from the Cannabis Sativa plant. Although CBD has the same chemical formula (C21H30O2) and is a nearly structurally identical isomer to ∆9-Tetrahydrocannabinol (THC), it has vastly different effects on the brain and body. Cannabidiol is non-intoxicating and non-psychedelic. It has anti-inflammatory, anti-convulsant, anti-anxiolytic and anti-psychotic effects. Recent research has shown that this small molecule has unique properties that reduce neuroinflammation and act as an antioxidant; thus, supporting its potential role as an effective adjunctive treatment for neurodegenerative and psychological disorders. CBD is widely used by the public for numerous applications including pain relief, nausea, and anxiety. Growing clinical research supports CBD in treatment of traumatic brain injury (TBI) recovery, epilepsy, and schizophrenia. There is still little known about the long-term effects of CBD on adults and adolescents. Therapeutic effects can range widely depending on dose and route of administration. CBD can readily cross the blood brain barrier (BBB) and interact with CB1 and CB2 receptors, though exactly how it interacts with these receptors is not fully understood. Current research has sparked interest in the administration of CBD in reducing drug-seeking behavior in patients with substance use disorders (SUDs). This pilot study aims to analyze how CBD alters addiction behavior as well as how it can be detected in the blood following intraperitoneal (IP) injection using an animal model. Our pilot suggests that rats receiving CBD injection show increased rates of active responding for sucrose compared to vehicle group. Further, following 20 mg/kg body weight IP injection of CBD, we can detect CBD in plasma via liquid chromatography-quadrupole time of flight mass spec (LC-QTOF). The ability to detect CBD levels in blood will allow for better analysis of ideal dosing for treatment of various symptoms as well as analyzing how CBD uptake varies by sex and its potential applications in treating SUDs.

Department

Behavioral Neuroscience

Subjects - Topical (LCSH)

Cannabis; Substance abuse; Marijuana abuse; Injections, Intraperitoneal

Type

Text

Rights

Copying of this document in whole or in part is allowable only for scholarly purposes. It is understood, however, that any copying or publication of this document for commercial purposes, or for financial gain, shall not be allowed without the author’s written permission.

Language

English

Format

application/pdf

Download

Included in

Neurosciences Commons

Share

COinS